Dr. Arash Pakseresht is an associate medical director working in the obesity, NASH and medical Info team at Novo Nordisk Canada. He originally joined Novo Nordisk Canada in 2016. Since then, his career has flourished at Novo Nordisk, both locally and globally. He joined Novo Nordisk HQ global medical affairs team in Denmark in 2019 to be part of the global Semaglutide obesity launch team. Dr. Pakseresht has co-authored several peer-reviewed publications in the field of obesity. He and other co-authors published STEP 2 primary manuscript in the Lancet. Dr, Pakseresht contributed to the first real-world evidence study on liraglutide 3.0 mg in Canada and was listed as one of the co-authors. In addition, as a member of the steering committee and co-author of the ACTION study in Canada, he has supported raising awareness of obesity as a chronic disease. Dr. Pakseresht is an MD and has completed a pharmaceutical MBA program at Rutgers Business School.